BioSpace News Archive

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Mark A. McCamish , MD, PhD, has joined Viracta as a Strategic Advisor to the Company. Dr. McCamish will provide strategic, financial and operational guidance to the Viracta leadership team as the Com

Dalrada Financial Corp. (OTC Pink: DFCO) is announcing to its shareholders and the public that Harvey Hershkowitz was appointed to Dalrada’s Board of Directors.

SQZ Biotechnologies (SQZ), a clinical stage cell therapy company developing novel treatments for multiple therapeutic areas, today announced the appointments of Paul Bolno, MD, to its board of directors, and Kai Wucherpfennig, MD, PhD, to its scientific advisory board. Dr. Bolno is the chief executive officer of Wave Life Sciences and brings over 15 years of experience in both corporate and scientific leadership. Dr. Wu

JW Therapeutics , a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, today announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS ® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries. This press rel

Darling Ingredients Inc. (NYSE: DAR), today announced that its Rousselot business, the global leader of collagen-based solutions, has successfully introduced X-Pure® GelMA at Bio Digital 2020.

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August 5, 2020, and will hold a conference call to discuss the results on August 5, 2020 at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID # 4458189.

Exero Medical , developer of a wireless sensor for early detection of anastomotic leaks following GI surgery, today announced it has completed the first human implantation of its sensor. The implant procedure was part

Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, will hold a conference call on Thursday, August 6, 2020 at 8:00 a.m. Eastern time to discuss its results for the second quarter ended June 30, 2020. A press release detailing these results will be issued prior to the call. Calyxt Chief Executive Officer Jim Blome, Chief Financial Officer Bill Koschak, Chief Science Officer Dan Voytas, Ph.D. and Chief

Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announce that John Celentano, a current independent director of Teligent, has been appointed Chairman of Teligent’s Board of Directors, replacing James C. Gale who opted to not stand for reelection to Teligent’s board of directors in order to devote more time to other business interests. Mr. Celentano joined Tel

Metaclipse, a late-stage biotechnology company developing next-generation vaccines with a particular focus on treatments for the elderly, has been awarded $2.2 million by the National Institute of Allergy and Infectious Diseases (NIAID) to support its efforts to develop a COVID-19 vaccine.